J Ginseng Res. 2023 Mar;47(2):246-254. doi: 10.1016/j.jgr.2022.08.003. Epub 2022 Aug 26.
BACKGROUND: Here, we aimed to assess the inhibitory effect of a new compound from Panax ginseng on the migration of human ovarian cancer cells and tube formation of human umbilical vein endothelial cells (HUVECs).
METHODS: A new compound, ginsenglactone A (1), was isolated from ginseng roots, together with seven known compounds (2–8). Spectroscopic data were used to elucidate the chemical structure of 1. The tubular structure formation in HUVECs was assessed by Mayer’s hematoxylin staining. The migration of A2780 cells was evaluated using the scratch wound healing assay.
RESULTS: HUVECs treated with 1 had the statistically significant decrease in tubular structure formation compared to the HUVECs treated with compounds 2–8. This effect was enhanced by co-treatment with inhibitors for phosphatidylinositol 3-kinase (PI3K) (LY294002) and extracellular signal-regulated kinase (ERK) (U0126). Treatment with 1 decreased the expression of phosphorylation of ERK, PI3K, vascular endothelial growth factor receptor2 (VEGFR2), Akt, and mammalian target of rapamycin (mTOR). In addition, the ability of A2780 cells to cover the scratched area were also decreased. This effect was enhanced by co-treatment with U0126. Lastly, treatment with 1 decreased the phosphorylation of ERK, matrix metalloproteinase-9 (MMP-9), and MMP-2.
CONCLUSION: These results suggest that ginsenglactone A is a potential inhibitor of HUVEC tubular structure formation and A2780 cellular migration, which may be helpful for understanding its anticancer mechanism.
PMID:36926606 | PMC:PMC10014176 | DOI:10.1016/j.jgr.2022.08.003